Biotech | February 21, 2022
Valneva receives funding for Covid-19 vaccine from Scotland
The grants are expected to be received over the next three years, commencing March 2022
The grants are expected to be received over the next three years, commencing March 2022
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
Evonik invests in start-up to improve patient recovery after open-chest surgery
Darolutamide is developed jointly by Bayer and Orion Corporation
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
Subscribe To Our Newsletter & Stay Updated
